Physician profile
Donna Leonardo
NPI 1053716332
$1,499.77
in general payments reported to CMS, 2019-2025
15 companies · $331 in 2025
The $331 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $221 · 2022: $134 · 2023: $298 · 2024: $516 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,144.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $251.52 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $181.68 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $161.13 | 2022-2025 | |
| Novo Nordisk INC | $154.63 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $133.96 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $112.90 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Sumitomo Pharma America, INC. | $112.55 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $99.17 | 2021-2024 | Veozah |
| Alk-Abello, INC | $97.79 | 2024-2025 | Grastek, Odactra, Ragwitek |
| Pfizer INC. | $58.70 | 2021-2024 | |
| Exact Sciences Corporation | $47.24 | 2023-2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $35.69 | 2021 | |
| Mylan Specialty L.P. | $18.77 | 2021 | |
| Endo Pharmaceuticals INC. | $17.87 | 2021 | |
| Amgen INC. | $16.17 | 2025 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Leonardo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.